Previous 10 | Next 10 |
BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced...
Gainers: Sidus Space (SIDU) +94%. Evoke Pharma (EVOK) +50%. Visionary Education Technology Holdings (VEDU) +37%. Heliogen (HLGN) +27%. Ribbon Communications (RBBN) +25%. Digital World Acquisition (DWACW) +22%. Wheels Up Experience (UP) +21%. Austin Gold (AUST) +21%. AeroClean Technologies (AE...
Gainers: Evoke Pharma EVOK +52%. Zynerba Pharmaceuticals (ZYNE) +18%. LifeMD (LFMD) +13%. Vivos Therapeutics (VVOS) +12%. ACADIA Pharmaceuticals ACAD +11%. Losers: 180 Life Sciences (ATNF) -31%. Belite Bio (BLTE) -19%. VectivBio VECT -14%...
VectivBio Holding (NASDAQ:VECT) has priced a follow-on public offering of 5.72M ordinary shares at a price of $5.25/share for aggregate gross proceeds of ~$30M. Underwriters are granted a 30-day option to purchase up to an additional 857,250 ordinary shares at the public offering price. Offer...
BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of a follow-on public offeri...
Clinical-stage biopharmaceutical company VectivBio Holding launched a follow-on public offering of ordinary shares and agreed to sell ~$20M worth ordinary shares to Forbion Growth Opportunities Fund II Coöperatief U.A. in a private placement transaction. For the public offering, size not...
BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the launch of a follow-on public offerin...
BASEL, Switzerland, June 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation to the 2022 Annual Genera...
– Interim proof-of-concept data anticipated from STARGAZE in H1 2023 – First-in-class regenerative, non-immunosuppressive approach to treating acute Graft-versus-Host Disease – Second clinical indication under evaluation for apraglutide, demonstratin...
Gainers: Palo Alto Networks (PANW) +11%. Bioceres Crop Solutions (BIOX) +7%. VectivBio Holding AG (VECT) +7%. Aveanna Healthcare Holdings (AVAH) +6%. Fate Therapeutics (FATE) +5%. Losers: Foghorn Therapeutics (FHTX) -26%. Ross Stores (ROST) -23%. Atara Biotherapeutics (A...
News, Short Squeeze, Breakout and More Instantly...
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of card...
Simplicity Esports (WINR) is expected to report for quarter end 2024-02-29 BankUnited Inc. (BKU) is expected to report $0.62 for Q1 2024 Winmark Corporation (WINA) is expected to report for Q1 2024 SL Green Realty Corp (SLG) is expected to report $2.17 for Q1 2024 Union Bankshares...
VectivBio Holding AG (VECT) is expected to report for quarter end 2023-12-31